Prevention and Treatment of HIV and Hepatitis C in People with Opioid Use Disorder
Launch Date
May 25, 2023
Expiration Date
May 25, 2024
Credits
1 Hour
AAPA, ACPE, AMA, CNE, CPE, ASWB, IPCE
Cost
There is no fee for this educational activity.
Universal Activity Number
N/A
Target Audience
HIV Case Managers, Pharmacists, Physician Assistants, Physicians, Providers, Psychologists, Registered Nurses, Social Workers
Activity Type
Among persons living with HIV in the United States, an estimated 15 to 30% have HCV coinfection. For persons living with HIV who have HCV coinfection, liver-related morbidity and mortality is a prominent non-AIDS-related complication—up to 80 to 90% of liver-related deaths in persons living with HIV are attributable to HCV infection-and proper treatment remains a priority. This webinar discusses HIV/HCV co-infection, particularly among people who inject drugs, and evidence-based prevention and treatment strategies.
Educational Objectives
After completing this activity, the participant should be better able to:
- Discuss the epidemiology of HIV and HCV infections in populations of people who use drugs, particularly those who inject drugs.
- Outline established and emerging strategies to prevent infection in these individuals.
- Evaluate the approach to treatment of HIV and HCV in these individuals.
Faculty
Mark Sulkowski MD, Johns Hopkins University